Some evidence derived through clinical trials suggests that methylated MGMT GBM may have a therapeutic advantage, based on adding nivolumab to standard therapy; on the other hand, in unmethylated MGMT GBM, HFSRT could be used to induce an immunogenic reaction that improves survival. The gene discussed is MGMT; the disease is glioblastoma.